Frontiers in Biostatistics: Group Sequential Design Assuming Delayed Benefit
February 9, 2021 1:00PM ET Keaven Anderson, PhD Scientific AVP, Methodology Research, Biostatistics at Merck Group Sequential Design Assuming Delayed Benefit Abstract: We consider an asymptotic approach to design of group sequential trials with a potentially delayed effects. Logrank, weighted logrank tests and combination tests are of primary interest, but we also consider restricted mean […]